Sysmex

Skip Navigation

SearchMenu

About Sysmex

Press Releases

Management & Business Management & Business
May. 08, 2013

Sysmex Strengthens Sales and Support in South Korea
- Transitioning to a Direct Sales and Support Organization with a View to Further Growth in Hematology and Non-Hematology Fields -

  Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has acquired its distributor in The Republic of Korea (hereinafter as South Korea), Dong Kang Medipia Co., Ltd. (HQ: Seoul, South Korea; Chairman and CEO: C.K. Lee) to establish a wholly-owned subsidiary. Sysmex shifts to a direct sales and support organization in South Korea, with the aim of further enhancing its presence and expanding its business in the country.

  The healthcare sector in South Korea is expected to expand further, with the national government investing aggressively to increase its sophistication, globalization and level of information technology. Faced with a declining birthrate and an aging population, by 2020 per capita government spending on healthcare is forecast to be the third highest in Asia, after Japan and Taiwan.


  Sysmex appointed Dong Kang Medipia as a local distributor in 1987 and commenced its business in South Korea. The sales and support activities that Dong Kang Medipia conducted have enabled Sysmex to acquire a substantial market share in its main business of hematology, as well as in hemostasis and urinalysis. In collaboration with Dong Kang Medipia, Sysmex also has cultivated strong relationships with key opinion leaders and taken a lead in promoting the Sysmex brand.


  By acquiring Dong Kang Medipia, Sysmex aims to complement the strengths that Dong Kang Medipia has developed, by promoting Sysmex's expertise in scientific support, SNCS®* and other proprietary Sysmex services, further enhancing customer satisfaction. In addition to launching Sysmex's new flagship model in hematology, the XN-Series, Sysmex expects to expand our business further in non-hematology fields, such as by introducing new products in hemostasis and entering immunochemistry.
 

  Going forward, Sysmex aims to strengthen its sales and support organization and provide Sysmex-unique support services as it strives to contribute to the development of healthcare in Asia.

Overview of New Subsidiary
Name:  Sysmex Korea Co., Ltd. 
Location:  Seoul, South Korea 
Representative:  Naohide Imamiya 
Capital:  190 million KRW 
Capital supplied by:  Sysmex Corporation 
Employees:  57 
Lines of Business:  Sales and support services for in vitro diagnostic instruments and reagents in South Korea

* An abbreviation for Sysmex Network Communication Systems, SNCS® is an online support service that connects the Customer Support Center and customers' products via an internet connection to provide real-time external quality control and scientific information and to monitor instrument conditions. A separate (paid) agreement is needed to use this service.

 

*Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "Press Releases"